3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
6
Neoplasms
3
Ovarian Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Neoplasms by Site
1
Medulloblastoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
ER+ HER2- Advanced Breast Cancer
1
Digestive System Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
22
pembrolizumab
21
Carboplatin
12
Radiotherapy
11
Paclitaxel
11
Brachytherapy
11
Drug Therapy
10
Bevacizumab
9
Blood Specimen Collection
7
Colposcopy
6
Specimen Handling
5
Injections
5
toripalimab
4
Taxes
4
Surveys and Questionnaires
4
Nivolumab
4
Mass Screening
4
Human Papillomavirus DNA Tests
4
Gemcitabine
4
Chemotherapy, Adjuvant
4
Chemoradiotherapy
4
spartalizumab
3
lenvatinib
3
camrelizumab
3
aldesleukin
3
Restraint, Physical
3
Radiation
3
Fulvestrant
3
Cyclophosphamide
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uterine Cervical Neoplasms
×
ribociclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled